AlphAIAlphAI — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Biotechnology

$ROIV

Roivant Sciences Ltd.

Roivant Sciences is a biopharmaceutical company that develops medicines through subsidiaries called Vants. Its pipeline includes brepocitinib, in development for autoimmune diseases; IMVT-1402, an antibody being developed for IgG-mediated autoimmune diseases; and mosliciguat, an inhaled medicine being studied for pulmonary hypertension associated with interstitial lung disease. Roivant also incubates discovery-stage companies and health technology startups that complement its biopharmaceutical business. Roivant’s Vants include Priovant, Immunovant and Pulmovant, which develop these drug candidates. The company assembles its pipeline through in-licensing or acquisition of drug candidates and may receive milestone and royalty payments from product agreements. It also develops and deploys computational tools and provides shared support functions to its Vants. Roivant is headquartered in London.

Next earnings date

ROIV is scheduled to report on Nov 9, 2026.

Confirmed by the company. We show nothing until it is. ROIV earnings →

Price · $ROIVvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $ROIV in the last 7 days.

Insider · 30dAll trades →
Buys
—
0 txs
Sells
$14.3M
3 txs
Venker Eric3× · $14.3M
10b5-1 share of filings100%
See all $ROIV insider activity →
Top stories · $ROIVMore →
OCT 30·SEC EDGARLow

Venker Eric sold $7.3M of ROIV

Venker Eric (President & Immunovant CEO) sold 200,000 shares of Roivant Sciences Ltd. (ROIV) at $36.59 ($7.32M total) on 2026-10-28 under a Rule 10b5-1 trading plan.

OCT 28·scanx.trade

Citigroup raises Roivant Sciences price target to $56, maintains Buy

Citigroup raised its price target for Roivant Sciences to $56 from $46, maintaining a Buy rating. The biopharmaceutical firm reported a cash position of nearly $4 billion, bolstered by a $950 million settlement with Moderna. Roivant plans to launch brepocitinib for dermatomyositis by September, pending FDA approval, and has multiple clinical readouts scheduled for 2026-2027.

OCT 22·SEC EDGAR

Venker Eric sold $7.0M of ROIV

Venker Eric (President & Immunovant CEO) sold 200,000 shares of Roivant Sciences Ltd. (ROIV) at an average of $35.11 ($35.09–$35.42, $7.02M total) across 2 trades on 2026-10-20 under a Rule 10b5-1 trading plan.

ROIV sentiment & insider activity

Recent ROIV coverage spans financial news, insider activity and market movers.

In the last 30 days, ROIV insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($14.3M). The most active reporter was Venker Eric, President & Immunovant CEO, with 3 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving ROIV

  • The insider sale may signal reduced confidence and could weigh on the stock.

    SEC EDGAR · Oct 30, 2026

  • Citigroup raised its price target for Roivant Sciences to $56 from $46, maintaining a Buy rating. The biopharmaceutical firm reported a cash position of nearly $4 billion, bolstered by a $950 million settlement with Moderna. Roivant plans to launch brepocitinib for dermatomyositis by September, pending FDA approval, and has multiple clinical readouts scheduled for 2026-2027.

    scanx.trade · Oct 28, 2026

  • The insider sale may signal reduced confidence and could weigh on ROIV price.

    SEC EDGAR · Oct 22, 2026

  • Positive trial data fuels short‑term rally.

    cnbc.com · Oct 21, 2026

  • Positive pivotal data likely lifts the stock as investors price in potential FDA approval and future sales.

    investing.com · Oct 21, 2026

AlphAI scores every news story that mentions ROIV with an AI model for sentiment and relevance, and aggregates insider trades from Roivant Sciences Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ROIV

Score
OCT 28Medscanx.trade

Citigroup raises Roivant Sciences price target to $56, maintains Buy

Citigroup raised its price target for Roivant Sciences to $56 from $46, maintaining a Buy rating. The biopharmaceutical firm reported a cash position of nearly $4 billion, bolstered by a $950 million settlement with Moderna. Roivant plans to launch brepocitinib for dermatomyositis by September, pending FDA approval, and has multiple clinical readouts scheduled for 2026-2027.

2 min read
OCT 21$METALowcnbc.com

Stocks making the biggest moves midday: SpaceX, Meta Platforms, Super Micro Computer, Roivant Sciences & more

Roivant Sciences shares rose 4% after its drug Lisraya met primary goals in trials. Bloom Energy gained 6% ahead of earnings. Bitcoin-linked stocks rose with BTC. Alphabet shares fell 2% as OpenAI models will be available on Google Cloud. Meta Platforms gained 2% ahead of earnings. SpaceX shares rose 10% after reporting a 161% revenue jump. Netflix shares fell 5% after narrowing its 2026 revenue forecast. AT&T slid 6% despite an earnings beat. Capital One gained 4% on strong Q3 earnings.

3 min read
OCT 21$ROIVHighAI 9/10investing.com

Roivant Sciences stock surges on positive uveitis trial data

Roivant Sciences (NASDAQ:ROIV) shares rose 9% premarket after announcing brepocitinib met all Phase 3 trial endpoints for non-infectious uveitis. The drug showed significant benefit over placebo in both CLARITY-1 and CLARITY-2 trials. Priovant Therapeutics, a Roivant subsidiary, plans to file a supplemental New Drug Application in the first half of 2027.

2 min read
OCT 21$ROIVHighAI 9/10SEC EDGAR 8-K

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)

Roivant Sciences Ltd. (ROIV) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) • Brepocitinib 45 mg once-daily achieved statistically significant benefit compared to placebo on the primary and all key seconda

2 min read
OCT 21$ROIVMedinvesting.com

Roivant’s brepocitinib meets primary endpoint in uveitis trials

Roivant Sciences (ROIV) reported that brepocitinib met primary endpoints in Phase 3 trials for non-infectious uveitis. The drug showed significantly longer time to treatment failure and higher steroid-free quiescence rates compared to placebo. Roivant plans to file a supplemental New Drug Application in early 2027. Brepocitinib is already approved for dermatomyositis.

2 min read
OCT 8$IMVTLowfinance.yahoo.com

IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class

Argenx's Sjögren’s trial failure caused Immunovant (IMVT) and Roivant (ROIV) stocks to slide, raising concerns about their similar studies. Wainwright maintained a 'Buy' rating on Argenx (ARGX) with a $1,202 price target. Retail sentiment shifted from bearish to bullish for ARGX, while IMVT and ROIV saw neutral and bearish sentiment, respectively. Year-to-date, IMVT is up 19%, ROIV up 55%, and ARGX down 4%.

3 min read

Related tickers

More in Biotechnology